MAL-856
Hair Loss / Alopecia
Key Facts
About Mallia Therapeutics
Mallia Therapeutics is a private, pre-clinical stage biotech leveraging a deep scientific foundation in immunology to develop novel regenerative therapies. Its platform centers on the MAL-856 molecule, a recombinant protein related to soluble sCD83, which is believed to resolve inflammation and activate tissue repair. The company is initially targeting significant unmet needs in alopecia, chronic wounds, and inflammatory skin disorders through a first-in-class mechanism. Operating as a virtual or highly collaborative entity, it advances its programs via a network of academic and industrial partners.
View full company profileAbout Mallia Therapeutics
Mallia Therapeutics is a private, pre-clinical stage biotech leveraging a deep scientific foundation in immunology to develop novel regenerative therapies. Its platform centers on the MAL-856 molecule, a recombinant protein related to soluble sCD83, which is believed to resolve inflammation and activate tissue repair. The company is initially targeting significant unmet needs in alopecia, chronic wounds, and inflammatory skin disorders through a first-in-class mechanism. Operating as a virtual or highly collaborative entity, it advances its programs via a network of academic and industrial partners.
View full company profileAbout Mallia Therapeutics
Mallia Therapeutics is a private, pre-clinical stage biotech leveraging a deep scientific foundation in immunology to develop novel regenerative therapies. Its platform centers on the MAL-856 molecule, a recombinant protein related to soluble sCD83, which is believed to resolve inflammation and activate tissue repair. The company is initially targeting significant unmet needs in alopecia, chronic wounds, and inflammatory skin disorders through a first-in-class mechanism. Operating as a virtual or highly collaborative entity, it advances its programs via a network of academic and industrial partners.
View full company profile